Bulk Deal: Healthcare stock jumps 4% after DII acquired 16.68 lakh equity shares

Synopsis:- Shares rose 4% after a domestic institutional investor bought 16.68 lakh shares worth ₹241.55 crore via a bulk deal. FY25 revenue grew 17% to ₹1,196 crore, while profit surged 66% to ₹149 crore, supported by strong product launches and a diversified 71-brand portfolio.

The shares of the healthcare company gained up to 4 percent from the intraday’s low after a prominent domestic Institutional Investor acquired 16.68 lakh equity shares via a Bulk deal.

With a market capitalization of Rs 8,851.09 crore, the share of CORONA Remedies were trading at Rs 1,458 per share, increasing around 1.64 percent as compared to the previous closing price of Rs 1,438.40 apiece.

Bulk deal

The share of CORONA Remedies have seen bullish movement after Invesco Mutual Fund picked up a 2.7% stake in the company through a sizable investment of  Rs 241.55 crore. The fund acquired 7 lakh shares at  Rs 1,434.20 and another 9.68 lakh shares at  Rs 1,457.42, reflecting strong institutional confidence in the company’s growth prospects.

Financial Highlights

The company delivered a healthy financial performance in FY25, with revenue rising 17% to Rs 1,196 crore from  Rs 1,014 crore in FY24. Profitability improved at a faster pace, as net profit jumped 66% to  Rs 149 crore, reflecting stronger margins, operating efficiency, and improved business momentum.

Corona Remedies has emerged as one of the fastest-growing pharmaceutical players in India, ranking second among the top 30 companies by domestic sales. Between MAT June 2022 and MAT June 2025, it delivered a strong CAGR of 16.77%, well above the industry average of 9.21%, driven by its focus on high-growth therapy segments.

Corona Remedies has outpaced the broader pharmaceutical industry through a stronger contribution from new product launches. Products crossing  Rs 5 crore in sales account for 14.43% of its portfolio, higher than the top 30 pharma companies at 11.40% and well above the overall Indian pharma market average of 5.60%, highlighting superior innovation-led growth.

Corona Remedies operates with a diversified portfolio of 71 brands driving strong domestic sales. For MAT June 2025, women’s healthcare led with a 28.56% contribution, followed by cardio-diabetes at 23.38%, pain management at 11.79%, and urology at 4.53%. Flagship brands like Myoril, COR, and Trazer hold leading positions, strengthening the company’s presence across key therapies.

The company’s emphasis on chronic and sub-chronic therapies has delivered steady, high-quality growth over recent years. Domestic sales from these segments rose sharply from  Rs 572.55 crore, forming 63.82% of revenue in MAT June 2022, to  Rs 1,001.31 crore, or 70.10%, by MAT June 2025, supporting more stable and profitable earnings.

Corona Remedies made a strong debut on the BSE, listing at  Rs 1,470 against an issue price of  Rs 1,062, delivering listing gains of  Rs 408 or 38.42%. The Rs. 655.37 crore IPO, priced in the  Rs 1,008– Rs 1,062 range, attracted healthy investor interest, reflecting confidence in the company’s growth outlook and fundamentals.

Corona Remedies Limited is an India-focused branded pharmaceutical formulations company engaged in developing, manufacturing, and marketing products in various therapeutic areas. These include women’s healthcare, cardiology, diabetology, pain management, and urology. The company operates two manufacturing facilities-one in Bhayla, Gujarat, and another in Solan, Himachal Pradesh.  

Written by Abhishek Singh

Disclaimer

The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Bulk Deal: Healthcare stock jumps 4% after DII acquired 16.68 lakh equity shares appeared first on Trade Brains.